EpiThany, Merck KGaA, Pfizer to evaluate combination of avelumab and EP-101 STEMVAC in breast cancer

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.

February 13, 2026

Vol.52 No.06

By Jacquelyn Cobb

Regulatory News

CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot

In the latest episode of Vinay Prasad’s extraordinary adventures at FDA, the agency (i.e. Dr. Prasad himself) has issued a Refusal-to-File letter to an mRNA-based influenza vaccine application.

February 13, 2026

Vol.52 No.06

By Claire Marie Porter

Black History Month Cancer History Project

Olopade: “The genetic basis of every cancer, or everything we do, starts in Africa.”
For Black History Month, Olopade reflects on mentorship, community, and her career in cancer genetics

When Olufunmilayo I. “Funmi” Olopade was born, the most common Nigerian career aspirations were pastor or teacher. Olopade’s father, a pastor, thought differently. He wanted his children to be scientists, economists, and doctors.

February 13, 2026

Vol.52 No.06

By Olufunmilayo I. Olopade, Robert A. Winn and Preston Willett

NCI

NCAB ad hoc group approves seven new, reissue concepts

The National Cancer Advisory Board’s ad hoc Working Group on Extramural Research Concepts and Programs on Feb. 6 voted to approve four new and three reissue concepts.

Science is winning the war on cancer—CMS shouldn’t disarm

In 1971, the National Cancer Act declared a war on cancer, making it a national priority to attack this scourge of diseases.

February 13, 2026

Vol.52 No.06

By John M. O’Brien

Clinical Trials & Tribulations

Why infection and immunity matter for Florida’s cancer patients

In Florida, cancer is part of daily life for thousands of families. It is the state’s second-leading cause of death. Each year, an estimated 115,000 Floridians receive a new cancer diagnosis and certain preventable or virus-linked cancers continue to impose avoidable burdens on communities across the state.

February 13, 2026

Vol.52 No.06

By Eduardo Sotomayor

EpiThany, Merck KGaA, Pfizer to evaluate combination of avelumab and EP-101 STEMVAC in breast cancer

YOU MAY BE INTERESTED IN

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot

Olopade: “The genetic basis of every cancer, or everything we do, starts in Africa.”
For Black History Month, Olopade reflects on mentorship, community, and her career in cancer genetics

NCAB ad hoc group approves seven new, reissue concepts

Science is winning the war on cancer—CMS shouldn’t disarm

Why infection and immunity matter for Florida’s cancer patients

Renew today!

Subscriber content

Never miss an issue!

Login

EpiThany, Merck KGaA, Pfizer to evaluate combination of avelumab and EP-101 STEMVAC in breast cancer

YOU MAY BE INTERESTED IN

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades agoLowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot

Olopade: “The genetic basis of every cancer, or everything we do, starts in Africa.”For Black History Month, Olopade reflects on mentorship, community, and her career in cancer genetics

NCAB ad hoc group approves seven new, reissue concepts

Science is winning the war on cancer—CMS shouldn’t disarm

Why infection and immunity matter for Florida’s cancer patients

Never miss an issue!

Login

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

Olopade: “The genetic basis of every cancer, or everything we do, starts in Africa.”
For Black History Month, Olopade reflects on mentorship, community, and her career in cancer genetics